[
    [
        {
            "time": "2018-01-02",
            "original_text": "AbbVie's RA Candidate Upadacitinib Gets FDA Priority Review",
            "features": {
                "keywords": [
                    "AbbVie",
                    "RA",
                    "Upadacitinib",
                    "FDA",
                    "Priority Review"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "AbbVie's RA Candidate Upadacitinib Gets FDA Priority Review",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Notable ETF Outflow Detected - IYH, ABT, MDT, ABBV",
            "features": {
                "keywords": [
                    "ETF",
                    "Outflow",
                    "IYH",
                    "ABT",
                    "MDT",
                    "ABBV"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "ETFs"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Notable ETF Outflow Detected - IYH, ABT, MDT, ABBV",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "U.S. settles with Teva over keeping generic drugs off market",
            "features": {
                "keywords": [
                    "U.S.",
                    "Teva",
                    "generic drugs",
                    "market settlement"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "U.S. settles with Teva over keeping generic drugs off market",
                "Correlation": 4,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Roche's (RHHBY) BLA for Lymphoma Drug Gets Priority Review",
            "features": {
                "keywords": [
                    "Roche",
                    "BLA",
                    "Lymphoma",
                    "Drug",
                    "Priority Review"
                ],
                "sentiment_score": 0.85,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Roche's (RHHBY) BLA for Lymphoma Drug Gets Priority Review",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]